OBJECTIVE Prior incidence estimates of psoriatic arthritis (PsA) vary considerably. We aimed to assess the annual incidence of clinically diagnosed PsA among adults in Sweden in 2014-2016, overall and stratified by age/sex/education/geography, and to investigate potential time trends in incidence in 2006-2018. Use of disease-modifying antirheumatic drugs (DMARDs) during the 2 years after diagnosis was also examined. METHODS Patients (aged ≥ 18 years) with incident clinically diagnosed PsA in Sweden were identified from the National Patient Register (NPR) and/or the Swedish Rheumatology Quality Register (SRQ). Population statistics, stratification variables, and DMARD information were retrieved from other nationwide registers. Incidence was estimated according to a base case (BC) definition (ie, ≥ 1 main International Classification of Diseases, 10th revision, diagnosis of PsA [L40.5/M07.0-M07.3] from rheumatology/internal medicine in NPR, or a PsA diagnosis in SRQ during the relevant year, and no prior such diagnoses) and 4 different sensitivity analysis case definitions. RESULTS The mean annual incidence of clinically diagnosed PsA among adults in Sweden in 2014-2016 was estimated at 21.77 per 100,000 person-years (PYs) at risk, according to the BC definition; 17.41 per 100,000 PYs at risk after accounting for diagnostic misclassification; and 15.78 to 28.83 per 100,000 PYs at risk across all sensitivity analyses. Incidence was slightly higher in female individuals, was lower in those with higher education (aged > 12 years), and peaked during the ages of 50 to 59 years. No apparent increasing or decreasing time trend was observed in 2006-2018. Within 2 years of diagnosis, 71.03% of patients had received DMARD therapy (22.37% biologic or targeted synthetic DMARDs). CONCLUSION From 2014 to 2016, the annual incidence of clinically diagnosed PsA in the adult Swedish population was approximately 20 per 100,000 PYs at risk. Two years after diagnosis, almost three-quarters of patients had received DMARD therapy.

中文翻译：

---

瑞典临床诊断的银屑病关节炎的发生率。


目的 银屑病关节炎 （PsA） 的既往发病率估计差异很大。我们旨在评估 2014-2016 年瑞典成年人临床诊断的 PsA 年发病率，总体并按年龄/性别/教育/地理分层，并调查 2006-2018 年发病率的潜在时间趋势。还检查了诊断后 2 年内病情缓解抗风湿药 （DMARDs） 的使用情况。方法 从国家患者登记册 （NPR） 和/或瑞典风湿病质量登记册 （SRQ） 中确定了瑞典临床诊断为 PsA 的患者 （≥ 18 岁）。种群统计、分层变量和 DMARD 信息从其他全国登记册中检索。根据基本情况 （BC） 定义 （≥即 1 主要国际疾病分类，第 10 次修订版，NPR 风湿病学/内科诊断为 PsA [L40.5/M07.0-M07.3]，或相关年份 SRQ 中的 PsA 诊断，并且既往无此类诊断）和 4 种不同的敏感性分析病例定义。结果 根据 BC 定义，2014-2016 年瑞典成年人临床诊断的 PsA 年平均发病率估计为每 100,000 人年 （PY） 21.77 例;在考虑诊断错误分类后，每 100,000 PY 中有 17.41 人处于风险中;在所有敏感性分析中，每 100,000 PY 中有 15.78 至 28.83 个风险。女性个体的发病率略高，受过高等教育的人 （年龄 > 12 岁） 较低，并在 50 至 59 岁之间达到高峰。2006—2018 年未观察到明显的时间增加或减少趋势。在诊断后 2 年内，71.03% 的患者接受了 DMARD 治疗 （22.37% 的患者接受了生物或靶向合成 DMARDs）。 结论 从 2014 年到 2016 年，瑞典成年人群临床诊断的 PsA 的年发病率约为每 100,000 名高危 PY 中有 20 例。诊断两年后，近四分之三的患者接受了 DMARD 治疗。